西妥珠單抗
單株抗體 | |
---|---|
種類 | ? |
目標 | ROR1 |
臨床資料 | |
其他名稱 | UC-961 |
法律規範狀態 | |
法律規範 |
|
識別資訊 | |
CAS號 | 1643432-38-5 |
UNII |
西妥珠單抗(英語:cirmtuzumab;開發代號:UC-961),或譯次妥珠單抗,是一種抗ROR1人源化單株抗體。[1][2]
它是一種處於早期臨床試驗中的實驗藥物,用於治療包括慢性淋巴細胞白血病(CLL)在內的多種癌症。[3][4]
參考資料
- ^ Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, et al. Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts. Blood. 2015, 126 (23): 1736 [2024-03-10]. doi:10.1182/blood.V126.23.1736.1736. (原始內容存檔於2019-09-13).
- ^ Researchers to test novel drug combination against toughest breast cancers. Medical Express. 2018-08-27 [2024-03-10]. (原始內容存檔於2023-04-06).
- ^ Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
- ^ 1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo. Lymphoma News Today. 2018-05-18 [2024-03-10]. (原始內容存檔於2023-04-07).